Infectious Diseases

Back to articles

Fluoroquinolones: Moxifloxacin linked to 10-fold increase in hypoglycemia risk, FDA warns of peripheral neuropathy


Patients with diabetes who were taking fluoroquinolone antibiotics had an increased risk of severe dysglycemia compared to those taking non-fluoroquinolone antibiotics. The risk differed among fluoroquinolones and was highest with moxifloxacin (Avelox—Bayer), which was associated with a 10-fold absolute increased risk for hypoglycemia. In an unrelated action, FDA is requiring label updates to all fluoroquinolones to warn of peripheral neuropathy risks.

Recent Articles